MSLT-II

1. 01

   Avoiding routine completion dissection is the leading reading, but regional control and selective exceptions remain

2. 02

   Clinical nodal presentation is a critical boundary; imaging can make that boundary less straightforward

3. 03

   Expert ultrasound and reliable follow-up are conditions of de-escalation, but routine ultrasound alongside CT/PET is contested

   Sample finding · free

   An X thread asked what extra value routine nodal ultrasound offers for sentinel-node-positive patients already receiving CT/PET surveillance.

   Source: X thread, 2026-05-27 · paraphrased; the full report links the source

4. 04

   Omitting dissection does not settle the adjuvant-treatment decision, particularly in lower-risk disease

   Sample finding · free

   A podcast speaker asked what benefit adjuvant PD-1 therapy offers in stage III melanoma when completion lymph-node dissection has been omitted.

   Source: podcast, 2024-12-10 · paraphrased; the full report links the source

5. 05

   Transplant-related constraints can produce a different local-treatment choice without proving a dissection benefit

6. 06

   The completion-dissection result is not read as a reason to abandon sentinel-node biopsy

7. 07

   Follow-up intensity is pragmatic and risk-sensitive; benefit from earlier systemic treatment remains an open question

8. 08

   Imaging should change a decision, but baseline timing and postoperative interpretation can also delay care

9. 09

   Surgical morbidity is a major rationale, but its weight varies by basin, occupation, and patient circumstances

10. 10

    Head-and-neck and vulvar discussions retain site-specific qualifications rather than a blanket extrapolation

11. 11

    Small deposits, assay differences, and nonsentinel-node ascertainment complicate risk interpretation

12. 12

    Implementation includes institutional variation, patient preferences, care ownership, and research infrastructure

The full report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified claims with exact source passages.

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

2015-11-03 → 2026-07-29

Cited window

2015-11-03 → 2026-07-29

Retrieved

2026-10-07

Title

A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node

Registry

NCT00297895

Study IDs

MSLT-II · P01CA029605 · R01CA189163

Sponsor

Saint John's Cancer Institute

Collaborators

National Institutes of Health (NIH), National Cancer Institute (NCI)

Design

Not applicable · interventional, randomized, parallel, na

Status

Completed

Enrollment

1,939 actual

Start

2004-09-30 actual

Primary completion

2019-09-30 actual

Primary endpoint

Melanoma-specific survival. This is defined as the time between the date of a subject's randomization (or date of CLND for those randomized to the CLND arm) and the date of death due to melanoma. Subjects are followed until death or 10yrs.

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
• –For 6 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
• –34 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
• –3 further source limits are recorded in the machine-readable scope of this record.
• –The reviewed material is not representative of all clinicians or all public commentary. Additional potentially relevant recordings were unavailable, and unnamed or differently transcribed trial references may be missing.
• –Overlapping releases and podcast/video versions cannot be counted as independent HCP opinions. Source volume does not establish consensus.
• –Some passages do not establish who spoke. Their full views remain attributed to unnamed speakers rather than to people listed in programs or participant information.
• –Some transcript wording remains uncertain. The low-volume immunotherapy passage does not establish whether treatment is omitted or administered, and the case summary does not clearly establish steroid exposure.
• –Reported guideline positions, approval access, study eligibility, endpoint summaries, and practice changes are dated speaker accounts unless expressly identified as verified contextual reporting. Differing retellings have not been silently reconciled.
• –Individual cases, small series, retrospective comparisons, biological hypotheses, and speculative subgroup explanations do not establish comparative efficacy or a surgery-benefit subgroup.
• –The complete later regional-control publication was unavailable; its supplied context should not be read as a complete assessment of that publication.
• –Professional profiles provide context, not passage attribution or additional evidentiary weight. Meredith Gunder, MD's clinical role is unresolved in the supplied professional context.

How reports are built and checked: Methods.

Last checked Oct 8, 2026. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

release 7cdbb8b6dae03d3d7e7c995ff85ea5d0cef74562f4404baa4655d89008213300

The same record as JSON or Markdown, or through the Erudio MCP server.

curl https://www.erudio.com/reports/mslt-ii-nct00297895.json
curl https://www.erudio.com/reports/mslt-ii-nct00297895.md

# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "mslt-ii-00297895" })